Oncotarget

Research Papers:

DcR3 combined with hematological traits serves as a valuable biomarker for the diagnosis of cancer metastasis

Junxin Li, Ni Xie, Jianhui Yuan, Lvyan Liu, Qiming Zhou, Xiaohu Ren, Qian Chen, Guizhong Zhang, Qingguo Ruan, Youhai H. Chen and Xiaochun Wan _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:107612-107620. https://doi.org/10.18632/oncotarget.22544

Metrics: PDF 679 views  |   HTML 2083 views  |   ?  


Abstract

Junxin Li1,2,*, Ni Xie3,*, Jianhui Yuan4,*, Lvyan Liu1, Qiming Zhou5, Xiaohu Ren4, Qian Chen1,2, Guizhong Zhang1, Qingguo Ruan1, Youhai H. Chen6 and Xiaochun Wan1

1Shenzhen Laboratory of Fully Human Antibody Engineering, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, University City of Shenzhen, Xili Nanshan, Shenzhen, 518055, P.R. China

2University of Chinese Academy of Sciences, Beijing, 100049, P.R. China

3Institute of Translation Medicine, Shenzhen Second People’s Hospital, Shenzhen, 518035, P.R. China

4Institute of Toxicology, Shenzhen Center for Disease Control and Prevention, Shenzhen, 518055, P.R. China

5Department of Oncology, Nanshan Hospital of Shenzhen, Shenzhen, 518055, P.R. China

6Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, 19104, USA

*These authors contributed equally to this work

Correspondence to:

Xiaochun Wan, email: xc.wan@siat.ac.cn

Keywords: DcR3; PDW; HGB; HCT; metastasis

Received: August 09, 2017     Accepted: October 30, 2017     Published: November 20, 2017

ABSTRACT

Decoy receptor 3 (DcR3) is abnormally up-regulated in many cancer cells. It may help cancer cells to escape from immune surveillance and establish metastatic lesions. However, whether DcR3 can be used as a biomarker for the diagnosis of cancer metastasis is unclear. In this study, sera from healthy controls and patients with different cancers were collected, and tested for their DcR3 levels by ELISA. Significantly elevated DcR3 levels were observed in the sera of patients with gastric cancer (2.04 ± 1.01, P = 0.0061), lymphoma (1.62 ± 0.75, P = 0.041), and breast cancer (1.53 ± 0.51, P = 0.023). DcR3 was found to be a suitable biomarker for identifying gastric cancer patients. Importantly, DcR3 was positively associated with platelet distribution width (PDW) (P = 2.45 × 10−6, R = 0.63) in metastatic cancers but negatively associated with hemoglobin (HGB) (P = 0.002, R = −0.59) and hematocrit (HCT) (P = 0.001, R = −0.62) in non-metastatic cancers. Combined with PDW, HGB and HCT, serum DcR3 could be used to predict the occurrence of cancer metastasis. These findings indicate that DcR3 could be used as a biomarker for the diagnosis of gastric cancer, and for cancer metastasis in combination with hematological traits.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 22544